ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

NCI Faces Major Cuts On Gramm-Rudman Sequestration; Grants, Centers, Trials Slashed

November 3, 1989

CCOP Q&A, List Of Research Bases

September 10, 1982

Rauscher To Leave ACS when It Moves To Atlanta; Gadberry To Retire In March; Other VPs Stay On

January 8, 1988

NCI CTEP Approved Trials For the Month of May

May 31, 2013

Selumetinib Displays Positive Results, 60% with Stable Disease

April 29, 2011

Blood Vessel Growth Inhibitor May Be Tested Against KS

August 16, 1991